English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

To develop and validate a RP-HPLC method for the determination of selected antileukemic drugs in bulk and pharmaceutical formulations using Design of experiments. Development of the chromatographic method is based on design of experiments (DOE) approach, utilizing two level full factorial design for screening and Box-Behnken experimental design for optimization. In order to identify the significant parameters for the optimization, by simultaneously registering the main, interaction and quadratic effects of three factors such as volume of methanol (X1), concentration of buffer(X2) and flow rate (X3) on the selected responses like capacity factor K1 of first eluted peak (Y1), resolution of critical peaks RS (1,2) (Y2) and amp; RS (2,3) (Y3) and retention time of last peak tR4 (Y4) as responses. Analytes were separated on a Onyx monolithicC18 (100×4.6mm) with mobile phase comprising Potassium dihydrogen orthophosphate (0.01M), Methanol and Acetonitrile in ratio of (30:34.29:35.71), with flow rate of 0.723 mL/min and p H 3.5 adjusted with dilute orthophosphoric acid. Total chromatographic analysis time per samples was approximately 5 Original Research Article minutes with DST(IS), IMT, IBT and SFN eluting with retention times of 2.64, 3.05 minutes respectively. Calibration curves were linear over selected range 0.997 for the all analytes. The method was sensitive with the LODs were 10.457, 13.07 and 26.169 ng/mL and LOQs were 31.68, 39.6 and 79.3ng/mL for IMT, IBT and SFN res terms of %RSD) was fond to be less than ImatinibGleevec, IbrutinibImbruvica and Sorafenib the potential of the proposed method for determination of all the three anti routine analysis for products of similar type and composition.

journal of pharmaceutical research international

Box-Behnken Design Approach for Optimization of a Liquid Chromatographic Method for the Determination of Anti Leukemic Drugs in Bulk and Pharmaceutical Formulations